Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - Kintor Pharmaceutical-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostics, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for the strategic cooperation is not to exceed RMB 370 million, aimed at establishing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]
科济药业-B(02171)获纳入恒生综合指数 有望成为港股通标的